Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 期刊論文 > Item 310903500/29058

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/29058

题名:	Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer
作者:	Changlai, SP;Tsai, CS;Ding, HJ;Huang, WT;Kao, A;Hsu, WH
贡献者:	附設醫院內科部呼吸治療科;China Med Univ Hosp, Div Pulm & Crit Care Med, Dept Med, Taichung 404, Taiwan;Chi Mei Med Ctr, Dept Radiol, Tainan, Taiwan;Tzu Chi Coll Technol, Hualien, Taiwan;I Shou Univ, Sch Med Radiat Technol, Kaohsiung, Taiwan;Yuanpei Univ Sci & Technol, Dept Radiol Technol, Hsinchu, Taiwan;China Med Univ Hosp, Dept Med, Div Pulm Crit care Med, Taichung, Taiwan
日期:	2003
上传时间:	2010-09-24 14:20:09 (UTC+8)
出版者:	HUMANA PRESS INC
摘要:	Background/Ainis: A recent pilot study suggested that 18% of patients with hepatitis C viral infection achieved a sustained response to a 6-month course of 200mg of oral amantadine alone with disappearance of serum. hepatitis C virus ribonucleic, acid. We prospectively studied 30 naive patients with chronic hepatitis C viral infection for the possible role of amantadine in improving the efficiency of interferon for the treatment of chronic, hepatitis C. Methodology: Patients were assigned into two groups on a double-blind-and randomized controlled basis. Placebo group received 4.5 MU of interferon alfa-2a thrice weekly and-oral placebo daily for 24 weeks. Amantadine group received a combination of the interferon and 200mg of oral amantadine daily for 24 weeks. Patients were observed and tested for blood chemistry every week for the initial 4 weeks and every 2 weeks thereafter during the treatment until 24 weeks. After the end of treatment, patients were followed up at 4-week intervals for an additional 12 months. Results: At the end of treatment, 5 (33.3%) patients responded to the combination therapy, and 7 (46.7%) patients, responded to interferon therapy alone. Twelve months after cessation of the treatment, 3 (21.4%) patients bad a sustained complete response to the combination therapy, and 3 (20.0%) patients had a sustained complete response to interferon alone (P=0.64). Conclusions: Amantadine does not increase the efficacy of interferon in the treatment of chronic hepatitis C.
關聯:	MEDICAL ONCOLOGY 20(3):247-253
显示于类别:	[台中附設醫院] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....